Specific augmentation of plantar skin blood flow by lipo-PGE1 assessed in tetrodotoxin- and NG-nitro-L-arginine treated rats

被引:13
作者
Chino, D [1 ]
Akimaru, S [1 ]
Kataha, K [1 ]
Ishii, K [1 ]
Nakayama, K [1 ]
机构
[1] Univ Shizuoka, Fac Pharmaceut Sci, Dept Pharmacol, Shizuoka, Japan
关键词
lipo-PGE(1); PGE(1)-CD; tetrodotoxin- and N-G-nitro-L-arginine-treated; rat; skin blood flow;
D O I
10.1097/00005344-200004000-00017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Vasodilating effects of prostaglandin E-1 incorporated in lipid microspheres (lipo-PGE(1)) were compared with those of prostaglandin E-1 (PGE(1)) or its cyclodextrin clathrated preparation (PGE(1)-CD) on plantar skin blood flow in rats treated with tetrodotoxin and N-G-nitro-L-arginine (L-NNA). Tetrodotoxin (50 mu g/kg, i.v.) could totally inhibit the pressor response to electrical stimulation of the spinal cord, and the reflex tachycardia due to the depressor response to acetylcholine. Furthermore, r-NNA (30 mg/kg, i.v.) was used to counteract the lowering of the systemic blood pressure and peripheral vascular tone by elimination of sympathetic nerve activity, and to maintain the arterial blood pressure at the control level. Lipo-PGE(1) increased planter skin blood flow 4 to 6 times more potently than PGE(1)-CD or PGE(1) in the treated rats. Furthermore, lipo- PGE(1) increased plantar skin blood flow about 3 times more selectively than PGE(1)-CD. We also assessed several vasodilators, including terbutaline, nitroprusside, nicardipine, and papaverine in tetrodotoxin- and L-NNA-treated rats. However, none of them could selectively increase plantar blood flow despite the prominent depressor responses achieved. These results suggest that PGE(1) preparations, especially lipo-PGE(1) could potently and selectively increase plantar skin blood flow in rats treated with tetrodotoxin and L-NNA.
引用
收藏
页码:630 / 637
页数:8
相关论文
共 38 条
[1]   EFFECT OF PROSTAGLANDIN E1 ON FOREARM BLOOD FLOW [J].
BEVEGARD, S ;
ORO, L .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1969, 23 (04) :347-&
[2]  
CARLSON LA, 1976, LANCET, V2, P810
[3]  
CARLSON LA, 1973, LANCET, V1, P155
[4]  
CARLSON LA, 1968, ACTA MED SCAND, V183, P423
[5]   TREATMENT OF VASOSPASTIC DISEASE WITH PROSTAGLANDIN-E1 [J].
CLIFFORD, PC ;
MARTIN, MFR ;
SHEDDON, EJ ;
KIRBY, JD ;
BAIRD, RN ;
DIEPPE, PA .
BRITISH MEDICAL JOURNAL, 1980, 281 (6247) :1031-1034
[6]   SEX-DIFFERENCES IN CONTROL OF CUTANEOUS BLOOD-FLOW [J].
COOKE, JP ;
CREAGER, MA ;
OSMUNDSON, PJ ;
SHEPHERD, JT .
CIRCULATION, 1990, 82 (05) :1607-1615
[7]   PROSTAGLANDINS - THEIR DISAPPEARANCE FROM AND RELEASE INTO CIRCULATION [J].
FERREIRA, SH ;
VANE, JR .
NATURE, 1967, 216 (5118) :868-&
[8]   A METHOD OF STIMULATING DIFFERENT SEGMENTS OF AUTONOMIC OUTFLOW FROM SPINAL COLUMN TO VARIOUS ORGANS IN PITHED CAT AND RAT [J].
GILLESPIE, JS ;
MACLAREN, A ;
POLLOCK, D .
BRITISH JOURNAL OF PHARMACOLOGY, 1970, 40 (02) :257-+
[9]   Effect of aging on arteriolar dilatation induced by prostaglandin E(1) incorporated in lipid microspheres [J].
Hirose, M ;
Chun, TY ;
Miyazaki, M .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 27 (05) :749-751
[10]   PROSTAGLANDINS A1, A2 AND 19-HYDROXY A1 - THEIR ACTIONS ON SMOOTH MUSCLE AND THEIR INACTIVATION ON PASSAGE THROUGH PULMONARY AND HEPATIC PORTAL VASCULAR BEDS [J].
HORTON, EW ;
JONES, RL .
BRITISH JOURNAL OF PHARMACOLOGY, 1969, 37 (03) :705-&